BR9811061A - 11-(4-[2-(2-hidroxietoxi) etila] -1- piperazinila) - dibenzo[b,f] [1,4] tiazepina cristalina, uso desta, processos para a preparação e purificação da mesma, e, composição farmacêutica - Google Patents

11-(4-[2-(2-hidroxietoxi) etila] -1- piperazinila) - dibenzo[b,f] [1,4] tiazepina cristalina, uso desta, processos para a preparação e purificação da mesma, e, composição farmacêutica

Info

Publication number
BR9811061A
BR9811061A BR9811061-6A BR9811061A BR9811061A BR 9811061 A BR9811061 A BR 9811061A BR 9811061 A BR9811061 A BR 9811061A BR 9811061 A BR9811061 A BR 9811061A
Authority
BR
Brazil
Prior art keywords
ethyl
thiazepine
dibenzo
crystalline
hydroxyethoxy
Prior art date
Application number
BR9811061-6A
Other languages
English (en)
Inventor
Evan William Snape
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of BR9811061A publication Critical patent/BR9811061A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

"11-(4-[2-(2-HIDROXIETOXI)ETILA]-1-PIPERAZINILA)-DIBENZO[ B,F] [1,4]TIAZEPINA CRISTALINA, USO DESTA, PROCESSOS PARA A PREPARAçãO E PURIFICAçãO DA MESMA, E, COMPOSIçãO FARMACêUTICA" 11-(4-[2-(2-hidroxietoxi) etila]-1-piperazinila)-dibenzo[b, f] [1,4]tiazepina cristalina (I) pode ser preparada mediante a crista;ização da 11-(4-[2-(2-hidroxietoxi)etila]-1-piperazinila-dibenzo[b, f] [1,4]tiazepina a partir de um solvente não aromático tal como acetato de etila, acetato de isobutila, isso-butilcetona de metila ou éter metil terc-butílico, preferivelmente na ausência de água. O material cristalino produzido pode ser convertido em um sal farmaceuticamente aceitável tal como um fumarato. O 11-(4-[2-(2-hidroxietoxi) etila]-1-piperazinila)-dibenzo[b, f] [1,4]tiazepina cristalino pode ser usado para tratar psicoses.
BR9811061-6A 1997-08-01 1998-07-28 11-(4-[2-(2-hidroxietoxi) etila] -1- piperazinila) - dibenzo[b,f] [1,4] tiazepina cristalina, uso desta, processos para a preparação e purificação da mesma, e, composição farmacêutica BR9811061A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9716161.6A GB9716161D0 (en) 1997-08-01 1997-08-01 Process
PCT/GB1998/002260 WO1999006381A1 (en) 1997-08-01 1998-07-28 A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent

Publications (1)

Publication Number Publication Date
BR9811061A true BR9811061A (pt) 2000-09-19

Family

ID=10816746

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811061-6A BR9811061A (pt) 1997-08-01 1998-07-28 11-(4-[2-(2-hidroxietoxi) etila] -1- piperazinila) - dibenzo[b,f] [1,4] tiazepina cristalina, uso desta, processos para a preparação e purificação da mesma, e, composição farmacêutica

Country Status (32)

Country Link
US (2) US6372734B1 (pt)
EP (2) EP1000043B1 (pt)
JP (2) JP2001512109A (pt)
KR (1) KR20010022241A (pt)
CN (1) CN1125058C (pt)
AT (2) ATE496037T1 (pt)
AU (1) AU739255B2 (pt)
BG (1) BG64796B1 (pt)
BR (1) BR9811061A (pt)
CA (1) CA2295792C (pt)
CY (2) CY2200162T2 (pt)
CZ (1) CZ299225B6 (pt)
DE (4) DE69842104D1 (pt)
EE (1) EE04550B1 (pt)
ES (2) ES2296575T3 (pt)
GB (2) GB9716161D0 (pt)
HK (2) HK1029992A1 (pt)
HU (1) HU228620B1 (pt)
ID (1) ID24219A (pt)
IL (1) IL133618A (pt)
MY (1) MY120999A (pt)
NO (1) NO20000484L (pt)
NZ (1) NZ501914A (pt)
PL (1) PL338384A1 (pt)
PT (2) PT1589008E (pt)
RU (1) RU2224754C2 (pt)
SI (2) SI1589008T1 (pt)
SK (1) SK287145B6 (pt)
TR (1) TR200000848T2 (pt)
TW (1) TW533207B (pt)
WO (1) WO1999006381A1 (pt)
ZA (1) ZA986904B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2000141A1 (en) * 2002-03-20 2008-12-10 Teva Pharmaceutical Industries Ltd. Methods for preparing crystalline quetiapine hemifumarate
US7071331B2 (en) 2003-02-22 2006-07-04 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof
US7238686B2 (en) * 2003-03-03 2007-07-03 Hetero Drugs Limited Polymorphs of quetiapine fumarate
EP1611138A1 (en) 2003-04-07 2006-01-04 Hetero Drugs Limited A novel crystalline form of dorzolamide hydrochloride
ES2223294B2 (es) 2003-08-08 2005-10-01 Vita Cientifica, S.L. Procedimiento de preparacion de un compuesto farmaceuticamente activo.
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
WO2006035293A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Polymorphic forms of quetiapine hemifumarate
WO2006056772A2 (en) * 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Salts of quetiapine
GB0425729D0 (en) * 2004-11-23 2004-12-22 Pliva Res & Dev Ltd Heterocyclic compounds
ES2234447B1 (es) * 2005-03-07 2006-03-01 Union Quimico-Farmaceutica S.A. Procedimiento para la obtencion de un derivado de 11-(4-sustituido-1-piperazinil)dibenzo(b,f)(1,4)tiazepina.
JP2008502707A (ja) 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
US20070072840A1 (en) * 2005-05-30 2007-03-29 Pandya Bhargav Polymorphic forms of quetiapine
EP1928849A1 (en) 2005-09-30 2008-06-11 Fermion Oy New crystallization process of quetiapine hemifumarate
EP1948628A1 (en) * 2005-10-28 2008-07-30 Fermion Oy Quetiapine hemifumarate purification by crystallization
US8389510B2 (en) * 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
CN101360502B (zh) * 2005-11-18 2012-03-14 阿斯利康公司 结晶形式
US20090215744A1 (en) * 2005-11-18 2009-08-27 Astrazeneca Ab Solid Formulations
CN101360503A (zh) * 2005-11-18 2009-02-04 阿斯利康公司 液体制剂
JP2009516705A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 塩の形態
CZ300451B6 (cs) * 2006-07-03 2009-05-20 Farmak, A. S. Zpusob prípravy solí 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanolu (quetiapinu) a jejich cištení
WO2008066620A2 (en) * 2006-10-20 2008-06-05 Concert Pharmaceuticals Inc. Dibenzothiazepine derivatives
ATE480227T1 (de) 2007-02-14 2010-09-15 Lesvi Laboratorios Sl Pharmazeutische zusammensetzungen mit quetiapinfumarat
EP2144892A2 (en) * 2007-03-29 2010-01-20 Teva Pharmaceutical Industries Ltd. Improved process for preparing quetiapine fumarate
WO2009004480A2 (en) * 2007-05-07 2009-01-08 Actavis Group Ptc Ehf Quetiapine salts and their polymorphs
US20090082334A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched quetiapine
EP2229364B1 (en) * 2007-12-05 2015-02-25 Janssen Pharmaceutica, N.V. Dibenzoazepine and dibenzooxazepine trpa1 agonists
SI2262486T1 (sl) 2008-08-01 2013-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Sestavek kvetiapina
US20100069356A1 (en) * 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
US20120071649A1 (en) 2009-03-04 2012-03-22 Ranbaxy Laboratories Limited Process for the preparation of quetiapine fumarate
WO2013024072A1 (en) 2011-08-12 2013-02-21 Qiagen Gmbh Method for isolating nucleic acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787249A (fr) 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound

Also Published As

Publication number Publication date
AU8549898A (en) 1999-02-22
ZA986904B (en) 1999-02-01
EP1589008B1 (en) 2011-01-19
TR200000848T2 (tr) 2000-08-21
HU228620B1 (en) 2013-04-29
ES2296575T1 (es) 2008-05-01
EE200000062A (et) 2000-10-16
SK287145B6 (sk) 2010-01-07
SI1000043T1 (sl) 2010-01-29
JP2001512109A (ja) 2001-08-21
BG64796B1 (bg) 2006-04-28
DE69841216D1 (de) 2009-11-19
NO20000484L (no) 2000-03-16
GB9814882D0 (en) 1998-09-09
CZ2000341A3 (cs) 2000-05-17
AU739255B2 (en) 2001-10-04
ID24219A (id) 2000-07-13
CN1125058C (zh) 2003-10-22
CA2295792A1 (en) 1999-02-11
TW533207B (en) 2003-05-21
DE98936529T1 (de) 2008-11-20
DE69842104D1 (de) 2011-03-03
EP1000043A1 (en) 2000-05-17
HUP0002663A3 (en) 2001-10-29
JP2009102345A (ja) 2009-05-14
IL133618A (en) 2004-02-08
IL133618A0 (en) 2001-04-30
EP1589008A1 (en) 2005-10-26
ES2296575T3 (es) 2010-02-05
ATE444959T1 (de) 2009-10-15
US6372734B1 (en) 2002-04-16
KR20010022241A (ko) 2001-03-15
CY2200162T2 (el) 2010-07-28
ES2296568T3 (es) 2011-05-06
CY2200161T2 (el) 2010-07-28
HK1029992A1 (en) 2001-04-20
EE04550B1 (et) 2005-10-17
ES2296568T1 (es) 2008-05-01
SK1302000A3 (en) 2000-06-12
PT1000043E (pt) 2009-11-30
PL338384A1 (en) 2000-10-23
CZ299225B6 (cs) 2008-05-21
NZ501914A (en) 2001-09-28
RU2224754C2 (ru) 2004-02-27
HUP0002663A2 (hu) 2001-09-28
CN1265101A (zh) 2000-08-30
HK1081962A1 (en) 2006-05-26
ATE496037T1 (de) 2011-02-15
EP1000043B1 (en) 2009-10-07
DE05011169T1 (de) 2008-11-06
NO20000484D0 (no) 2000-01-31
CA2295792C (en) 2007-04-17
GB9716161D0 (en) 1997-10-08
WO1999006381A1 (en) 1999-02-11
US20020147186A1 (en) 2002-10-10
MY120999A (en) 2005-12-30
BG104176A (en) 2000-08-31
SI1589008T1 (sl) 2011-04-29
PT1589008E (pt) 2011-03-23

Similar Documents

Publication Publication Date Title
BR9811061A (pt) 11-(4-[2-(2-hidroxietoxi) etila] -1- piperazinila) - dibenzo[b,f] [1,4] tiazepina cristalina, uso desta, processos para a preparação e purificação da mesma, e, composição farmacêutica
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR9808069B8 (pt) diarilpropilaminas, composição farmacêutica e uso das mesmas, bem como processo para preparação das referidas diarilpropilaminas.
MX9204881A (es) Composicion farmaceutica que comprende moleculas activas, receptoras de calcio.
BR9913948A (pt) Composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e processo para o tratamento de dor aguda
BR9506847A (pt) Composto composição farmacêutica uso de um composto processo para o tratamento da dor
AR003662A1 (es) Una formulacion de liberacion continua de 11-[4-[2-(2-hidroxietoxi)etil]-1- piperazinil] dibenzo-[b, f][1, 4]tiazepina; usos en la fabricacion de medicamentos y un proceso para preparar dicha formulacion
BR9908458A (pt) Tiolésteres de ácido 11beta-benzaldoxim-estra-4,9-dien-carbÈnico substituìdos por s, processos para a sua preparação e preparados farmacêuticos contendo estes compostos
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
BR0111933A (pt) Uso de ácido pamÈico ou um de seus derivados, ou um de seus análogos, para a preparação de um medicamento para o tratamento de doenças caracterizadas por depósitos de agregados amilõides
DE69734764D1 (de) Eine amidgruppe tragende schwefelhaltige verbindungen, verfahren zu ihrer herstellung, deren verwendung in medikamenten und sie enthaltende pharmazeutische zubereitungen
EP1211251A4 (en) CHROMONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
DE69411387D1 (de) Verfahren zur Herstellung von pharmazeutisch aktiven Benzothiazepinderivaten.
BR0014469A (pt) Processo para melhorar a solubilidade de um derivado de amino álcool tricìclico, composição farmacêutica, processo para preparar a mesma, e, derivado de amino álcool tricìclico
BR9810031A (pt) Derivados de ácido pirrolidina carboxìlico como antagonistas á endotelina
SE9401480L (sv) En ny 78-resters polypeptid (NK-lysin) och dess användning
AR015164A1 (es) Nuevas 1-aril-3-heteroaril-tioureas sustituidas y 1-aril-3-heteroaril-isotioureas sustituidas como agentes antiateroscleroticos, su uso en la manufacturade un medicamento y composicion farmaceutica que las contiene
BR0008545A (pt) Processo para a preparação de um composto, e, composto
BR9911340A (pt) Compostos, uso de compostos, e, processo de regulação de meiose.
BR9806902A (pt) Composto, formulação farmacêutica, uso de um composto, e processos para produzir um composto e uma formulação farmacêutica.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SYNGENTA LIMITED (GB)

Free format text: ALTERADO DE: ZENECA LIMITED

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA UK LIMITED (GB)

Free format text: TRANSFERIDO DE: SYNGENTA LIMITED

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O C/C ART. 13 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]